Agilent Technologies (A) Stock Forecast & Price Target

Agilent Technologies is viewed positively because its synchronized product cycles are driving broad-based demand, with liquid chromatography up low double digits, gas chromatography orders running 2x plan, and new ICP-MS funnel exceeding $60 million, while Q3 organic sales rose 7.3% and Life Sciences and Diagnostics grew about 10%. The company also benefits from structural exposure to sticky end markets, including roughly 25% of sales tied to drug manufacturing and strong traction in pharma reshoring, where five of the top 10 pharma customers have already placed orders and revenue contribution is expected in 2027. Its diversified mix and operating discipline add resilience, as Chemical and Advanced Materials grew 7% organically, pharma-related revenue advanced 9% organically excluding CDMO, and margin expansion supported an EPS beat, reinforcing confidence in sustained growth despite some cyclical and China-related volatility.

Agilent Technologies is viewed negatively because its expected margin expansion may prove harder to achieve despite management’s recent operating-leverage messaging, as tariffs, sales phasing, and weather can all disrupt execution. The company is more sensitive than peers to the macroeconomic cycle, with about 25% of sales tied to chemical and advanced materials and roughly 10% to environmental/forensics, while 18% of sales come from China, about 50% above the peer average of ~12%. It also faces pressure from evolving sustainability disclosure rules, emissions and product-lifecycle risks, and the possibility of weaker research, healthcare, or government spending that could slow growth and compress profitability.